# Forma Therapeutics (stock symbol: FMTX) Logo in transparent PNG and SVG formats

## Forma Therapeutics Logo large

### Forma Therapeutics Logo large Download PNG (37.41 KB)

![Forma Therapeutics Logo large Download PNG (37.41 KB)](/img/orig/FMTX_BIG-35a98de3.png)

### Forma Therapeutics Logo large Download SVG (4.35 KB)

![Forma Therapeutics Logo large Download SVG (4.35 KB)](/img/orig/FMTX_BIG-a9430470.svg)

## Forma Therapeutics Logo icon format

### Forma Therapeutics Logo icon format Download PNG (57.34 KB)

![Forma Therapeutics Logo icon format Download PNG (57.34 KB)](/img/orig/FMTX-52df7ed5.png)

### Forma Therapeutics Logo icon format Download SVG (955 Bytes)

![Forma Therapeutics Logo icon format Download SVG (955 Bytes)](/img/orig/FMTX-4fd4fbff.svg)

## Forma Therapeutics Logo large for dark backgrounds

### Forma Therapeutics Logo large for dark backgrounds Download PNG (22.28 KB)

![Forma Therapeutics Logo large for dark backgrounds Download PNG (22.28 KB)](/img/orig/FMTX_BIG.D-d70b34c4.png)

### Forma Therapeutics Logo large for dark backgrounds Download SVG (4.33 KB)

![Forma Therapeutics Logo large for dark backgrounds Download SVG (4.33 KB)](/img/orig/FMTX_BIG.D-9fb62c30.svg)

## Forma Therapeutics Logo icon format for dark backgrounds

### Forma Therapeutics Logo icon format for dark backgrounds Download PNG (32.24 KB)

![Forma Therapeutics Logo icon format for dark backgrounds Download PNG (32.24 KB)](/img/orig/FMTX.D-9f1bbd53.png)

### Forma Therapeutics Logo icon format for dark backgrounds Download SVG (930 Bytes)

![Forma Therapeutics Logo icon format for dark backgrounds Download SVG (930 Bytes)](/img/orig/FMTX.D-e852460f.svg)

## About Forma Therapeutics

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.

1. Website domain: formatherapeutics.com
2. Employees: 189
3. Marketcap: $1.00 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
